Pfizer, Moderna Shares Plummet Amid Breaking News of Child Deaths Linked to Covid Shots

Friday, 12 September 2025, 16:47

Breaking news reveals that Pfizer and Moderna shares are facing a decline due to reports that Trump officials will link child deaths to Covid shots. This development raises significant concerns within the health care industry and impacts pharmaceutical companies. Stakeholders should monitor the ongoing discussions as they unfold in the United States and beyond.
Cnbc
Pfizer, Moderna Shares Plummet Amid Breaking News of Child Deaths Linked to Covid Shots

Breaking News: Business Impact on Pharma Due to Child Deaths Claims

Shares of Pfizer Inc and Moderna Inc are falling following a report that Trump officials plan to connect child deaths to Covid shots. This alarming claim will be part of a presentation to a crucial vaccine panel that advises the CDC on shot access and coverage.

Health Care Industry Concerns

The health care industry is on high alert as the potential ramifications become clear.

  • Pharmaceutical companies like Novavax Inc are watching closely.
  • This situation could affect market perceptions of biotech and pharmaceuticals.
  • Experts emphasize the significance of addressing social issues surrounding vaccines.

Implications for Business News

Such breaking news necessitates immediate attention from investors and analysts.

  1. Continuous monitoring of stock performance is recommended.
  2. Stakeholders should prepare for fluctuations in business valuations.
  3. Public sentiment may influence future health care decisions.

Visit our website for more details as this story develops.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe